Bosentan
- Generic Name
- Bosentan
- Brand Names
- Stayveer, Tracleer
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O6S
- CAS Number
- 147536-97-8
- Unique Ingredient Identifier
- XUL93R30K2
- Background
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
- Indication
Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
- Associated Conditions
- NYHA Functional Class II-IV Pulmonary arterial hypertension, Ocular Inflammation, Ocular bacterial infections
- Associated Therapies
- -
Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
- Target Recruit Count
- 48
- Registration Number
- NCT00637065
- Locations
- 🇬🇧
St George's Hospital, London, United Kingdom
🇬🇧Hammersmith Hospital, London, United Kingdom
🇬🇧Royal Brompton Hospital, London, United Kingdom
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Actelion
- Target Recruit Count
- 128
- Registration Number
- NCT00631475
- Locations
- 🇺🇸
USCF-Interstitial Lung Disease Center, San Francisco, California, United States
🇺🇸UAB Division of Pulmonary, Birmingham, Alabama, United States
🇺🇸Pulmoary and Critical Care Medicine-Stanford University Medical Center, Stanford, California, United States
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
- Conditions
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Rajan Saggar
- Registration Number
- NCT00625469
- Locations
- 🇺🇸
David Geffen School of Medicine UCLA, Los Angeles, California, United States
🇺🇸Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Pulmonary Artery Remodelling With Bosentan
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Actelion
- Target Recruit Count
- 11
- Registration Number
- NCT00595049
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, Australia
Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
- Conditions
- Interventions
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 43
- Registration Number
- NCT00581607
- Locations
- 🇺🇸
Mount Sinai, New York, New York, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Combination Therapy in Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Actelion
- Target Recruit Count
- 100
- Registration Number
- NCT00433329
- Locations
- 🇺🇸
UCLA - David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Morton Plant Hospital (Bay Area Chest Physicians, P.A.), Clearwater, Florida, United States
🇺🇸University of Pittsburgh Medical Center - Presbyterian, Pittsburgh, Pennsylvania, United States
BUILD 3: Bosentan Use in Interstitial Lung Disease
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Actelion
- Target Recruit Count
- 616
- Registration Number
- NCT00391443
- Locations
- 🇺🇸
UAB Division of Pulmonary, Birmingham, Alabama, United States
🇺🇸St. Luke's Medical Group, Cardio-Pulmonary Research, Chesterfield, Missouri, United States
🇺🇸UCSD Medical Center, San Diego, California, United States
Placebo Controlled Trial of Bosentan in Scleroderma Patients
- Conditions
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 5
- Registration Number
- NCT00377455
- Locations
- 🇺🇸
University of Connecticut, Farmington, Connecticut, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study
- Conditions
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2010-02-12
- Lead Sponsor
- Actelion
- Target Recruit Count
- 236
- Registration Number
- NCT00360087
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸St. Louis University, St. Louis, Missouri, United States
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2021-02-01
- Target Recruit Count
- 105
- Registration Number
- NCT00323297
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸West Los Angeles VA Healthcare, Pulmonary Hypertension Program, Los Angeles, California, United States
🇺🇸Diagnostics Research Group, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.